These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31100478)

  • 21. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
    Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
    PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.
    Rycaj K; Cho EJ; Liu X; Chao HP; Liu B; Li Q; Devkota AK; Zhang D; Chen X; Moore J; Dalby KN; Tang DG
    Oncotarget; 2016 Mar; 7(12):14220-40. PubMed ID: 26871947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress.
    Gonzalez-Menendez P; Hevia D; Alonso-Arias R; Alvarez-Artime A; Rodriguez-Garcia A; Kinet S; Gonzalez-Pola I; Taylor N; Mayo JC; Sainz RM
    Redox Biol; 2018 Jul; 17():112-127. PubMed ID: 29684818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gambogic Acid Inhibits Malignant Melanoma Cell Proliferation Through Mitochondrial p66shc/ROS-p53/Bax-Mediated Apoptosis.
    Liang L; Zhang Z
    Cell Physiol Biochem; 2016; 38(4):1618-30. PubMed ID: 27119348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
    Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
    Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion.
    Yu Y; Zhang Q; Ma C; Yang X; Lin R; Zhang H; Liu Y; Han Z; Cheng J
    Stem Cell Res Ther; 2018 Sep; 9(1):242. PubMed ID: 30257726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module.
    Zhao K; Li S; Wu L; Lai C; Yang G
    J Biol Chem; 2014 Jul; 289(30):20824-35. PubMed ID: 24942741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.
    Shiota M; Yokomizo A; Tada Y; Inokuchi J; Kashiwagi E; Masubuchi D; Eto M; Uchiumi T; Naito S
    Oncogene; 2010 Jan; 29(2):237-50. PubMed ID: 19802001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
    Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
    Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
    Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
    Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy.
    Rajan P; Sudbery IM; Villasevil ME; Mui E; Fleming J; Davis M; Ahmad I; Edwards J; Sansom OJ; Sims D; Ponting CP; Heger A; McMenemin RM; Pedley ID; Leung HY
    Eur Urol; 2014 Jul; 66(1):32-9. PubMed ID: 24054872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.
    Miller DR; Tzeng CC; Farmer T; Keller ET; Caplan S; Chen YS; Chen YL; Lin MF
    Cancer Lett; 2018 Nov; 436():96-108. PubMed ID: 30077739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.